Capital World Investors Has $985.44 Million Position in Exact Sciences Co. (NASDAQ:EXAS)

Capital World Investors grew its stake in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 10.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 17,537,617 shares of the medical research company's stock after purchasing an additional 1,696,321 shares during the period. Capital World Investors owned about 9.48% of Exact Sciences worth $985,439,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Asset Planning Inc purchased a new position in shares of Exact Sciences in the fourth quarter worth approximately $40,000. Modus Advisors LLC acquired a new position in Exact Sciences in the 4th quarter worth approximately $43,000. AlphaQuest LLC grew its position in Exact Sciences by 22,825.0% during the 4th quarter. AlphaQuest LLC now owns 917 shares of the medical research company's stock worth $52,000 after purchasing an additional 913 shares in the last quarter. SBI Securities Co. Ltd. acquired a new stake in Exact Sciences during the 4th quarter valued at $66,000. Finally, Kieckhefer Group LLC purchased a new stake in shares of Exact Sciences in the fourth quarter valued at $188,000. Institutional investors and hedge funds own 88.82% of the company's stock.

Analyst Ratings Changes

Several research firms recently weighed in on EXAS. Piper Sandler dropped their price target on Exact Sciences from $75.00 to $70.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Bank of America decreased their price target on shares of Exact Sciences from $72.00 to $65.00 and set a "buy" rating for the company in a report on Thursday, February 20th. Scotiabank upped their price objective on shares of Exact Sciences from $70.00 to $73.00 and gave the company a "sector outperform" rating in a research note on Monday, February 24th. Guggenheim reiterated a "buy" rating and issued a $60.00 target price on shares of Exact Sciences in a research report on Friday, April 11th. Finally, Benchmark restated a "buy" rating and set a $65.00 price target on shares of Exact Sciences in a report on Monday, January 13th. Two investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Exact Sciences has a consensus rating of "Moderate Buy" and an average target price of $69.25.

Exact Sciences Stock Performance

Shares of EXAS stock traded down $0.05 during mid-day trading on Friday, reaching $45.56. The stock had a trading volume of 460,517 shares, compared to its average volume of 2,604,163. The firm has a market cap of $8.46 billion, a PE ratio of -8.21 and a beta of 1.14. The company has a quick ratio of 1.93, a current ratio of 2.15 and a debt-to-equity ratio of 0.97. Exact Sciences Co. has a one year low of $39.97 and a one year high of $72.83. The firm's 50 day simple moving average is $45.42 and its 200 day simple moving average is $54.38.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.23. The firm had revenue of $713.42 million for the quarter, compared to analyst estimates of $701.45 million. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. On average, analysts forecast that Exact Sciences Co. will post -0.58 EPS for the current year.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.